Neoadjuvant strategies for pancreatic cancer

Table 2 Studies on chemotherapy for advanced pancreatic cancer

Ref.	CT regimen	Study	LAPC (n)	ORR (%)	OS median	Res rate (%)	Metastatic	ORR (%)	OS median
Conroy et al[33]	FOLFIRINOX vs Gem	Multicentric phase II trial	0	NA	NA	NA	342	31.6 vs 9.4	11.1 vs 6.4
Louvet et al[45]	GEMOX vs GEM alone	phase III	98	14.9 vs 27.3	10.3 vs 10.3	NA	215	18.3 vs 26.4	6.7 vs 8.5
Rocha Lima et al[46]	Irinotecan + GEM vs GEM alone	Multicenter, open label, phase III	51	25.9 vs 4.2	9.8 vs 11.7	NA	293	14.9 vs 4.8	5.4 vs 5.9
Poplin et al[47]	GEM vs GEM FDR vs GEMOX	phase II, multicentric	86	36	9.2	NA	737	NR	4.9 vs 6.2 vs 5.7
Kindler et al[49]	GEM + Bevacizumab vs GEM + placebo	Double blind, placebo controlled, phase III	31	NA	NA	NA	189	NR	5.8 vs 5.9
Gunturu et al[53]	FOLFIRINOX	Single centre, retrospective	16	50	NA	NA	19	47	NA
Peddi et al[55]	FOLFIRINOX	Registry	18	34	NA	NA	22	18	NA

CT: Chemotherapy; LAPC: Locally advanced pancreatic cancer; ORR: Overall response rate; OS: Overall survival; Res: Resection; NA: Not available; NR: Not reported; FOLFIRINOX: 5-fluorouracil + leucovorin + oxaliplatin + irinotecan; GEM: Gemcitabine; GEM FDR: Gemcitabine fixed dose ratio.